Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax) and Trastuzumab in High-risk HER2+ Breast Cancer Patients

Trial Profile

Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax) and Trastuzumab in High-risk HER2+ Breast Cancer Patients

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Nelipepimut-S (Primary) ; Sargramostim; Trastuzumab
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Sep 2017 According to a Galena Biopharma media release, results from the primary endpoint of the trial are expected in the fourth quarter of 2019.
    • 28 Sep 2017 Status changed from recruiting to active, no longer recruiting according to a Galena Biopharma media release.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top